search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Iranian Journal of Reproductive Medicine
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences of Yazd
ISSN: 1680-6433
EISSN: 2008-2177
Vol. 11, No. 10, 2013, pp. 837-842
Bioline Code: rm13105
Full paper language: English
Document type: Research Article
Document available free of charge

Iranian Journal of Reproductive Medicine, Vol. 11, No. 10, 2013, pp. 837-842

 en Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study
Torabizadeh, Aalie; Vahidroodsari, Fatemeh & Ghorbanpour, Zakieh

Abstract

Background: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability.
Objective: Comparison of albumin and cabergoline in the prevention of OHSS.
Materials and Methods: 95 high risk infertile women for OHSS (more than 20 follicles in both ovaries at day of Human Chorionic Gonadotropin (HCG) injection) were randomly divided into two groups. First group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second group including 47 women received 0.5 mg/day dopamine agonist (Cabergolin) at day of HCG injection till 8 days. The dosage of human Menopausal Gonadotropin (HMG) used, total number of follicles developed, number of oocytes retrieved, serum E2 concentrations during the luteal phase, development of ascites, number of embryos generated, clinical pregnancy rate, results of the in vitro fertilization-embryo transfer (IVF-ET) cycles and incidence and severity of any OHSS were evaluated.
Results: There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergolin group (53.7%) versus albumin group (46.3%) (p=0.04). But there was no significant difference of a reduction in severe OHSS (p=0.62). There was no difference in clinical pregnancy rate too.
Conclusion: Administration of cabergolin can prevent incidence of OHSS and does not appear to effect on its severity.

Keywords
Ovarian hyperstimulation syndrome (OHSS); Cabergolin; Assisted reproductive technology (ART); Albumin

 
© Iranian Journal of Reproductive Medicine
Alternative site location: http://www.ijrm.ir

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2017, Site last up-dated on 05-Dec-2017.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil